Morgan Stanley Infla Rx N.V. Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Infla Rx N.V. stock. As of the latest transaction made, Morgan Stanley holds 626,599 shares of IFRX stock, worth $833,376. This represents 0.0% of its overall portfolio holdings.

Number of Shares

626,599

Previous 693,854 9.69%

Holding current value

$833,376

Previous $548,000 49.64%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$0.8 - $1.73 $53,804 - $116,351	-67,255 Reduced 9.69%	626,599 $820,000
Q2 2025 Aug 15, 2025	SELL	$0.73 - $1.85 $414,492 - $1.05 Million	-567,798 Reduced 45.0%	693,854 $548,000
Q1 2025 May 15, 2025	SELL	$1.02 - $2.62 $792,044 - $2.03 Million	-776,514 Reduced 38.1%	1,261,652 $1.29 Million
Q4 2024 Feb 14, 2025	BUY	$1.38 - $2.64 $1.89 Million - $3.62 Million	1,370,035 Added 205.05%	2,038,166 $5.08 Million
Q3 2024 May 14, 2025	SELL	$1.34 - $1.73 $213,998 - $276,281	-159,700 Reduced 19.29%	668,131 $1.02 Million

Q3 2024 Nov 14, 2024	SELL	$1.34 - $1.73 $213,998 - $276,281	-159,700 Reduced 19.29%	668,131 $1.02 Million
Q2 2024 May 14, 2025	SELL	$1.18 - $1.74 $1.43 Million - $2.11 Million	-1,210,335 Reduced 59.38%	827,831 $1.44 Million
Q2 2024 Oct 17, 2024	SELL	$1.18 - $1.74 $177,814 - $262,200	-150,690 Reduced 15.4%	827,831 $1.44 Million
Q2 2024 Aug 14, 2024	SELL	$1.18 - $1.74 $177,814 - $262,200	-150,690 Reduced 15.4%	827,831 $1.44 Million
Q1 2024 Oct 17, 2024	BUY	$1.47 - $2.03 $221,514 - $305,900	150,690 Added 18.2%	978,521 $1.51 Million
Q1 2024 Aug 16, 2024	BUY	$1.47 - $2.03 $81,879 - $113,070	55,700 Added 6.04%	978,521 $1.51 Million
Q1 2024 May 15, 2024	BUY	$1.47 - $2.03 $81,879 - $113,070	55,700 Added 6.04%	978,521 $1.51 Million
Q4 2023 Aug 16, 2024	BUY	$1.25 - $2.75 $118,737 - $261,222	94,990 Added 11.47%	922,821 $1.5 Million
Q4 2023 Feb 13, 2024	BUY	$1.25 - $2.75 $360,876 - $793,927	288,701 Added 45.53%	922,821 $1.5 Million
Q3 2023 Nov 15, 2023	BUY	$2.66 - $4.33 $11,172 - $18,186	4,200 Added 0.67%	634,120 $1.89 Million
Q2 2023 Aug 14, 2023	SELL	$2.05 - $6.1 $30,979 - $92,183	-15,112 Reduced 2.34%	629,920 $2.81 Million
Q1 2023 May 15, 2023	SELL	$1.66 - $3.1 $5,976 - $11,160	-3,600 Reduced 0.56%	645,032 $1.25 Million
Q4 2022 Feb 14, 2023	SELL	$2.11 - $3.25 $98,631 - $151,921	-46,745 Reduced 6.72%	648,632 $2.01 Million
Q3 2022 Nov 14, 2022	SELL	$1.32 - $3.14 $96,828 - $230,334	-73,355 Reduced 9.54%	695,377 $1.84 Million
Q2 2022 Oct 27, 2022	BUY	$0.78 - $1.9 $9,906 - $24,130	12,700 Added 1.68%	768,732 $1.12 Million
Q2 2022 Aug 15, 2022	BUY	$0.78 - $1.9 $9,906 - $24,130	12,700 Added 1.68%	768,732 $1.12 Million
Q1 2022 Oct 27, 2022	SELL	$1.83 - $4.48 $23,241 - $56,896	-12,700 Reduced 1.65%	756,032 $1.38 Million
Q1 2022 May 13, 2022	SELL	$1.83 - $4.48 $215,261 - $526,977	-117,629 Reduced 13.46%	756,032 $1.38 Million
Q4 2021 Feb 14, 2022	BUY	$2.35 - $5.58 $354,112 - $840,827	150,686 Added 20.84%	873,661 $4.16 Million
Q3 2021 Nov 15, 2021	BUY	$2.25 - $3.03 $1.63 Million - $2.19 Million	722,975 New	722,975 $1.87 Million

Others Institutions Holding IFRX

# of Institutions

Shares Held

19.2M

Call Options Held

52K

Put Options Held

View Full List

About InflaRx N.V.

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $58.8M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

More about IFRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account